Skip to main content
    T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $93.91
    +1.70 (+1.84%)

    Market Cap: $3.20B

    Last updated: Nov 17, 2026 at 4:30 PM ET

    TransMedics Group Inc (TMDX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    TransMedics Group (TMDX) has a market cap of $3.20B and an enterprise value of $3.57B. Revenue grew 28.48% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 11.50% above the market cap, as debt exceeds cash.

    Market Cap$3.20B
    Enterprise Value$3.57B
    Latest price (Nov 17, 2026)$93.91

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.32% in the quarter ended Sep 30, 2026 and grew 1.85% a year over 2 years.

    Shares Outstanding34.69M
    Shares Change (YoY)+1.70%
    Shares Change (QoQ)+0.32%
    Share Count Growth (2Y CAGR)+1.85%

    Valuation Ratios

    Sales and book value multiples are 4.5x and 5.9x. Its year-end P/E ranged from 52.2x to 986.6x from 2023 to 2025.

    P/E Ratio72.2x
    Forward P/E55.0x
    P/S Ratio4.5x
    Forward P/S4.2x
    P/B Ratio5.9x
    P/TBV Ratio6.1x
    P/FCF Ratio72.9x
    P/OCF Ratio28.5x
    PEG Ratio2.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 26.1x EBITDA and 81.1x free cash flow.

    EV / Earnings24.7x
    EV / Sales4.9x
    EV / EBITDA26.1x
    EV / EBIT36.2x
    EV / FCF81.1x

    Price Statistics

    The stock is down 18.35% over 52 weeks and trades 16.75% above its 50-day average.

    Beta (1Y)1.20
    52-Week Change-18.35%
    1-Month Change+31.16%
    3-Month Change-0.06%
    6-Month Change+42.01%
    5-Year Change+140.58%
    Total Return (1Y)-18.35%
    Total Return (3Y CAGR)+10.98%
    Total Return (5Y CAGR)+32.52%
    Return vs SPY (1Y)-31.34%
    Max Drawdown (1Y)-58.76%
    Max Drawdown (3Y)-67.79%
    Sharpe Ratio (1Y)-0.35
    Correlation with SPY (1Y)0.26
    50-Day Average$80.44
    200-Day Average$91.22
    52-Week Range$60.10 to $156.00
    RSI (14 Days)68.3
    Average Volume (20 Days)1.22M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.53x current liabilities, and total debt is 1.56x shareholder equity.

    Current Ratio4.53x
    Quick Ratio4.15x
    Debt / Equity1.56x
    Debt / EBITDA6.19x
    Debt / FCF19.27x
    Interest Coverage3.94x

    Returns and Efficiency

    Return on invested capital is 6.99% over the last 12 months, against a 5-year average of 9.53%.

    Return on Equity (ROE)26.23%
    Return on Assets (ROA)9.52%
    Return on Invested Capital (ROIC)6.99%
    Return on Capital Employed (ROCE)7.23%
    ROE (5Y Average)-9.40%
    ROA (5Y Average)-5.43%
    ROIC (5Y Average)9.53%
    Asset Turnover0.59x
    Inventory Turnover5.35x
    Receivables Turnover6.64x
    Cash Conversion Cycle109 days

    Scores

    TMDX has an Altman Z-Score of 2.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score2.92
    Altman Z ZoneGrey
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $727.65M over the last 12 months.

    Revenue$727.65M
    Revenue Growth (YoY)+28.48%
    Gross Profit$426.43M
    Operating Income$86.45M
    Pretax Income$73.62M
    Net Income$144.45M
    EBITDA$139.06M
    EBIT$98.64M
    Reported EPS (TTM)$1.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 36.23% of the $1.52B in total assets.

    Cash and Equivalents$492.96M
    Total Debt$861.35M
    Net Debt$368.38M
    Net Debt Per Share$10.62
    Working Capital$539.60M
    Shareholder Equity$550.71M
    Book Value Per Share$15.87
    Tangible Book Value$529.88M
    Tangible Book Per Share$15.27
    Total Assets$1.52B
    Total Liabilities$967.23M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $67.66M of capital spending, operating cash flow left $44.70M of free cash flow.

    Operating Cash Flow$112.36M
    Capital Expenditures$67.66M
    Free Cash Flow$44.70M
    FCF Per Share$1.29
    Depreciation and Amortization$40.41M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 11.88%, against a 5-year average of -29.88%.

    Gross Margin58.60%
    Operating Margin11.88%
    Pretax Margin10.12%
    Net Margin19.85%
    EBITDA Margin19.11%
    EBIT Margin13.56%
    FCF Margin6.14%
    Gross Margin (5Y Average)64.56%
    Operating Margin (5Y Average)-29.88%
    Net Margin (5Y Average)-31.15%

    Growth

    Revenue grew 86.42% a year over 3 years.

    Revenue Growth (3Y CAGR)+86.42%
    Revenue Growth (5Y CAGR)+88.21%
    Book Value Per Share Growth (2Y CAGR)+69.69%
    Tangible Book Per Share Growth (2Y CAGR)+76.75%

    Revenue and profit by year

    Dividends and Yields

    TMDX does not pay a dividend. Its free cash flow yield is 1.37%.

    Earnings Yield1.39%
    FCF Yield1.37%
    Buyback Yield-0.12%
    Shareholder Yield-0.12%

    Peer Position

    Against 9 similar companies, TMDX has the 2nd highest P/E and the 3rd highest ROIC.

    P/E Ratio72.2x vs 23.6x median
    P/S Ratio4.5x vs 3.2x median
    ROIC6.99% vs 4.74% median
    Revenue Growth (Trailing 4 Quarters, YoY)+28.48% vs +7.73% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 22.01% and EPS growth at 3.27% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+22.01%
    EPS Growth Forecast (2Y CAGR)+3.27%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TMDX

    What is TMDX's market cap?

    TransMedics Group has a market cap of $3.20B. Its enterprise value, which adds debt and subtracts cash, is $3.57B.

    What is TMDX's P/E ratio?

    TransMedics Group has a trailing P/E ratio of 72.2x and a forward P/E of 55.0x.

    How many shares of TMDX are outstanding?

    TransMedics Group has 34.69M shares outstanding. The count is up 1.70% from a year earlier.

    Does TMDX pay a dividend?

    No. TransMedics Group does not pay a dividend.

    How much debt does TMDX have?

    TransMedics Group has $861.35M of total debt and $492.96M of cash and equivalents, a net debt position of $368.38M.